A Phase II, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma

What is the purpose of this trial?

Prospective, single-arm interventional study evaluating autologous tumor infiltrating lymphocyte (TIL) infusion (LN-144) followed by IL-2 after a non-myeloablative chemotherapy preparative regimen for the treatment of metastatic melanoma.

Lion Biotechnologies, Inc.

Start Date: 01/20/2016

End Date: 03/31/2020

Last Updated: 04/28/2019

Study HIC#: 1506016045

Get Involved

For more information about this study, contact:
Neta Shanwetter Levit
+1 203-737-6247

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image